Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data for its investigational drug, SIL204, designed to target KRAS mutations in various cancers. The data revealed inhibition rates of 97% in pancreatic cancer cells and 90% in colorectal cancer cells, marking a significant step forward in developing therapies for some of the most aggressive forms of cancer.
The results represent the company’s first evidence of safety and efficacy against the KRAS Q61H mutation, a clinically important but previously untested target in human cancer cells. SIL204 continues to demonstrate its promise as a pan-KRAS therapeutic candidate, addressing multiple KRAS mutations across cancer types.
Building on Prior Studies
The new data builds upon earlier studies that tested SIL204’s activity across various cancer models. Using CellTiter-Glo (CTG) analysis, researchers performed a direct comparison of SIL204’s effectiveness against multiple KRAS mutations. The study also showed dose-dependent inhibition of up to 94% in pancreatic cells with KRAS G12D mutations, and notably, 87% inhibition in cells with the KRAS Q61H mutation, a mutation previously unexplored by Silexion.
These results follow earlier findings that demonstrated SIL204’s effectiveness in lung cancer cell lines, providing further validation of Silexion’s lipid-conjugated delivery platform for RNAi-based cancer therapeutics.
Executive Insight
Silexion Chairman and CEO Ilan Hadar commented on the development:
“These findings have provided engaging evidence of SIL204’s potential activity against various KRAS mutations across multiple cancer types. The capability to achieve such a level of inhibition in colorectal and pancreatic cancer models with multiple KRAS mutations exponentially strengthens SIL204’s ability as a pan-KRAS therapeutic candidate.”
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
He added:
“With these positive results in all three crucial KRAS-targeted cancer types lung, pancreatic, and colorectal—we are elevating our confidence in SIL204’s potency to address major unmet needs for severe cancer patients.”
Path Forward
Silexion is now preparing to advance SIL204 into Phase 2/3 clinical trials in Q2 2026, focusing on KRAS-driven solid tumors. The trials will incorporate both systemic and intratumoral delivery approaches, part of the company’s dual-path administration strategy aimed at maximizing therapeutic impact.
The strong preclinical evidence across multiple KRAS mutations positions SIL204 as a potentially transformative treatment option in the oncology space, particularly for patients battling treatment-resistant forms of cancer.
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
